Compare AbbVie Inc (ABBV) vs Lucid Group Inc (LCID) Price & Performance

AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.

Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.

Lucid Group (LCID) trades at $7.04, up 0.86% with a neutral technical signal despite recent earnings misses. The company reported Q2 2026 revenue of $405.3 million (beating estimates) but a wider loss of $3.30 per share due to inventory charges. Management is executing a $1.4 billion operational reset focusing on cost reductions, robotaxi partnerships, and delaying the Cosmos EV launch to 2027. Financial metrics show severe challenges with negative gross margins of -96.56% and net income margin of -249.21%.

The outlook remains high-risk with persistent cash burn and competitive pressures, though analyst consensus targets $10.50 representing 49% upside. Key risks include execution of the turnaround plan, EV market demand, and the need for future capital raises. The stock offers speculative potential if cost savings materialize but faces significant fundamental headwinds.